SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up

SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the Company will be included in the Russell Microcap® Index effective after the U.S. market opens on Monday, June 28, 2021, as based on the preliminary list of additions. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. “Inclusion in the Russell Microcap® Index represents another important milestone for SELLAS and is an achievement that will undoubtedly increase awareness and visibility of our company within the investment community,” said Angelos Stergiou, MD, ScD hc, President and Chief Executive Officer, SELLAS. “Our inclusion is a testament to our diligent work on our clinical development programs for our lead asset, galinpepimut-S (GPS) which have the potential to result in a treatment for multiple cancer indications that will help patients to stay in remission and live longer. We look forward to sharing the SELLAS story as well as updates on our execution and milestones, which are currently on track, with a wider investor audience as part of the FTSE Russell Microcap® Index.”

SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares rallied Tuesday as retail traders try to push the stock higher. The stock is likely continuing its momentum after the company secured a U.S. patent for cancer combo therapy.

Sellas Life Sciences Stock May Have Broken Out Of Pennant Pattern: What's Next?

Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher by 8.3% at $8.24 after the company reported first-quarter EPS results up from last year. Sellas Life Sciences reported quarterly losses of 16 cents per share, which represents a marked improvement over losses of 66 cents per share from the same period last year.

What's Up With Sellas Life Sciences Stock Today?

Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China

SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

SELLAS Life Sciences to Host Shareholder Update Call on June 3rd

Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Galinpepimut-S in China; Additional $1 Million Milestone Triggered in February 2021

SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update

NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in the Emerging Growth Virtual Conference hosted by M Vest LLC and Maxim Group, LLC on Wednesday, March 17, 2021.

SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th

SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company developing novel cancer immunotherapies. Sellas is currently progressing two therapeutics GalinPepimut-S (Phase 3, Fast Track, ODD) and Nelipepimut-S (Phase 2) across 4 indications with GPS aiming for a 2023 approval in CR2 AML.

Sellas: Late-Stage Biotech Approaches 2023 Approval With Solid Funding

Shares of SLS stock are up after SELLAS Life Sciences was mentioned heavily on Reddit. Who is this company?

SLS Stock: 8 Things to Know About SELLAS Life Sciences as It Enjoys Reddit Bump

The stock price of Sellas Life Sciences Group Inc (NASDAQ: SLS) is trading at over 50% pre-market today as of 4:37 AM ET. This is why it happened.

SLS Stock Price Increases Over 50% Pre-Market: Why It Happened

-  Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe  -

SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

Greenwich Lifesciences

Immutep Ltd

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for effective treatments.

Shares of Startup Biotechs Soar on Cancer Study Results

- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks  and 100% Progression Free Survival at 6 Weeks -

SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - 

SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million

NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreement with institutional investors to purchase approximately $16.2 million of its common stock in a registered direct offering at a purchase price of $7.00 per share.

SELLAS Announces Pricing of $16.2 Million Registered Direct Offering

Solid Biosciences

vTv Therapeutics

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction in HbA1c. Tv Therapeutics Inc operates in the United States health care sector.

Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences

– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –

SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast

SLS stock is surging today as investors grow interest in a cancer vaccine from SELLAS Life Sciences in the wake of a rally in GLSI stock. The post SLS Stock: Why SELLAS Life Sciences Is Surging Today appeared first on InvestorPlace.

SLS Stock: Why SELLAS Life Sciences Is Surging Today

- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -

SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China

- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -

SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results

NEW YORK, Sept.  09, 2020  (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:  SLS ) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has received approval of its Investigational Medicinal Product Dossier (IMPD) from the French regulatory authority,  Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), to advance in France its pivotal Phase 3 REGAL study of galinpepimut-S (GPS) in patients with Acute Myeloid Leukemia (AML) who have achieved complete remission after second-line anti-leukemic therapy (CR2). 

SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia

- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market -   - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple data readouts expected in next 18 months -

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results

Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study

News for SELLAS Life Sciences Group Stock (SLS)